secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2023-01-19T23:59:59+00:00
Accession:  0001171843-23-000338
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics reports positive Phase 2 data for CTX-009 in biliary tract cancers; ORR 37.5%
--------------------------------------------------------------------------------

- CTX-009 + paclitaxel achieved 37.5% ORR in 24 patients; second-line sub-group ORR 63.6% (7/11 PRs).
- Median PFS 9.4 months, median OS 12.5 months; data to be presented at ASCO GI on Jan 20, 2023.
- Randomized Phase 2/3 trial (up to 150 patients) initiated in US; may enable BLA submission in H2 2024.
- Safety consistent with prior studies; Grade 3+ TEAEs included decreased neutrophils (83.3%), hypertension (16.7%).
- Investor webcast scheduled for Jan 23 at 8:30am ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184323000338/0001171843-23-000338-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184323000338/f8k_011923.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-000338

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer